How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Novel biomarkers for early diagnosis of Acute Kidney Injury

Organization name

ascenion GmbH



Acute Kidney Injury (AKI) is a rapid loss of kidney function that can be triggered by a number of disease or disorder processes. AKI can result in life-threatening metabolic derangements, e.g. acidosis, high potassium levels, changes in body fluid balance, and effects to other organ systems. AKI is observed in 5% of hospitalized patients and associated with a high mortality. Knowing the specific patient status in disease progression over time is critical for choosing ideal treatment regimens, in particular in the acute disease phase. Biomarkers in use so far, such as serum creatinine and blood urea nitrogen, do not sufficiently allow for such precise resolution, raising a demand for new early stage markers.


The technology relates to the use of newly identified AKI biomarkers specific for early stages, allowing for detailed estimation of disease progression over time. The technology is based on the detection of three novel markers (confidential) alone or in combination with known markers. The novel AKI-markers are expressed with peak expression at 6 hours or 48 hours after AKI onset, respectively. The expression profiles allow the detection of the markers at mRNA and/or protein level in blood, tissue or urine samples, thus representing a valid diagnostic tool to facilitate AKI diagnosis and to monitor disease progression and resolution. So far, the assay format is based on mRNA microarray analysis, but can be extended to protein techniques.

Developmental Status

Progression stage-specific biomarker expression was shown in a mouse AKI model using ischemia reperfusion injury and mRNA detection.

Commercial Opportunity

In-licensing for the development of diagnostic tools; collaboration opportunity.

Patent Situation

A European and a US Patent Application are pending (unpublished, confidential).

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries